Find research datasets worth reusing

Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy

ClinicalTrials.gov study NCT02352129. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Diagnostic and Prognostic Value of New Biomarkers in Patients With Heart Disease

ClinicalTrials.gov study NCT01374880. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Prognostic Value of CTC in HNSCC Patients

ClinicalTrials.gov study NCT01884129. IPD Sharing: Not stated. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →

Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network

ClinicalTrials.gov study NCT07203495. IPD Sharing: YES. Countries: 1. Publications: 4.

Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes

ClinicalTrials.gov study NCT02117037. IPD Sharing: Not stated. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →

Prognostic Value of AIMS65 Score to Predict Outcome in Patients With Acute Upper Gastrointestinal Bleeding

ClinicalTrials.gov study NCT05773339. IPD Sharing: YES. Countries: 1. Publications: 4.

Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism

ClinicalTrials.gov study NCT01908231. IPD Sharing: Not stated. Countries: 2. Publications: 11.

Prognostic Value of Myocardial Fibrosis in Severe Aortic Valve Stenosis

ClinicalTrials.gov study NCT03585933. IPD Sharing: UNDECIDED. Countries: 2. Publications: 1.

Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma.

ClinicalTrials.gov study NCT04213664. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.

closedIPD-NOFeb 2026View details →

Frailty in Patients With Cirrhosis: Prognostic Value of the Phase Angle in Hospitalized Patients and Effect of Multifactorial Intervention

ClinicalTrials.gov study NCT04243148. IPD Sharing: NO. Countries: 1. Publications: 2.

opencc-zeroDec 2017View details →

Data from: Prognostic value of ki67 in BCG-treated non-muscle invasive bladder cancer: a meta-analysis and systematic review

Objectives: The aim of this study was to explore the prognostic value of ki67 as a marker in non-muscle-invasive bladder cancer (NMIBC) patients treated with Bacillus Calmette–Guérin (BCG). Methods: Studies were systematically retrieved from the relevant databases (Web of Science, PubMed, Cochrane Library, and Embase), and the expiry date was May 2017. The research steps referred to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. Results: A total of 11 studies that complied with the inclusion criteria were enrolled. The expression of ki67 was not statistically significantly associated with recurrence-free survival (RFS) [hazard ratio (HR): 1.331; 95% CI: 0.980–1.809)]. No significant heterogeneity was found among all included studies (I2 = 36.7%, P = 0.148). The expression of ki67 was statistically significantly associated with progression-free survival (PFS) (HR: 2.567; 95% CI: 1.562–4.219), and the overexpression of ki67 was the risk factor for PFS. Significant heterogeneity was noted among all the included studies (I2 = 55.6%, P = 0.021). The studies that might cause heterogeneity were excluded using the Galbraith plot, and then the meta-analysis was performed again. The results showed that the expression of ki67 was still associated with PFS (HR: 2.922; 95% CI: 2.002–4.266). Conclusions: The overexpression of ki67 was the risk factor for PFS, and the relationship between the expression of ki67 and RFS was not statistically significant in patients with NMIBC treated with BCG intravesical immunotherapy. Well-designed, prospective, randomized controlled trials with a large sample size are still needed to validate the findings.

opencc-zeroDec 2016View details →

Data from: Characteristics of patients included and enrolled in studies on the prognostic value of serum biomarkers for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic review

Objective: Mild traumatic brain injury (mTBI) has been insufficiently researched and its definition remains elusive. Investigators are confronted by heterogeneity in patients, mechanism of injury and outcomes. Findings are thus often limited in generalizability and clinical application. Serum protein biomarkers are increasingly assessed to enhance prognostication of outcomes but their translation into clinical practice has yet to be achieved. A systematic review was performed to describe the adult populations included and enrolled in studies that evaluated the prognostic value of protein biomarkers to predict post-concussion symptoms following a mTBI. Data sources: Searches of MEDLINE, EMBASE, CENTRAL, CINAHL, Web of Science, PsycBITE, and PsycINFO up to October 2016. Data selection and extraction: Two reviewers independently screened for potentially eligible studies, extracted data and assessed the overall quality of evidence by outcome using the Grading of Recommendations Assessment, Development and Evaluation approach. Results: A total of 23,298 citations were obtained from which 166 manuscripts were reviewed. Thirty-six cohort studies (2,812 patients) having enrolled between 7 and 311 patients (median 89) fulfilled our inclusion criteria. Most studies excluded patients based on advanced age (n=10 (28%)), neurologic disorders (n=20 (56%)), psychiatric disorders (n=17 (47%)), substance abuse disorders (n=13 (36%)) or previous TBI (n=10 (28%)). Twenty-one studies (58%) used at least two of these exclusion criteria. The pooled mean age of included patients was 39.3 (SD 4.6) years old (34 studies). The criteria used to define a mTBI were inconsistent. The most frequently reported outcome was post-concussion syndrome (PCS) using the Rivermead Post-Concussion Symptoms Questionnaire (n=18 (50%)) with follow-ups ranging from 7 days to 5 years after the mTBI. Conclusions: Most studies have recruited samples that are not representative and generalizable to the mTBI population. These exclusion criteria limit the potential use and translation of promising serum protein biomarkers to predict post-concussion symptoms.

zenodo28/100

Neutrophil/Lymphocyte Ratio has a Prognostic Value for Patients with Terminal Cancer

datasets

opencc-zeroApr 2016View details →

opencc-zeroJul 2022View details →

Risk stratification and prognostic value of basic coagulation parameters among COVID-19 patients

Background: COVID-19 is a viral disease caused by a new strain of coronavirus. Currently, prognosis and risk stratification of COVID-19 patients is done by the disease's clinical presentation. Therefore, identifying laboratory biomarkers for disease prognosis and risk stratification of COVID-19 patients is critical for prompt treatment. Therefore, the main objective of this study was to assess the risk stratification and prognostic value of basic coagulation parameters and factors associated with disease severity among COVID-19 patients, Northwest Ethiopia. Methods: A follow-up study was conducted among conveniently recruited COVID-19 patients attended from March to June 2021. Socio-demographic and clinical data were collected using a structured questionnaire and checklist, respectively. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were analyzed by the HUMACLOT DUE PLUS® machine. Descriptive statistics were used to summarize the socio-demographic and clinical characteristics of study participants. Kruskal Wallis tests were used to compare the difference between parametric and non-parametric continuous variables, respectively. The area under the receiver operating characteristic curve (AUC) was used to evaluate the value of PT and APTT in the risk stratification and disease prognosis of COVID-19 patients. Ordinal logistic regression was used to identify the factors associated with disease severity and prognosis. A P-value < 0.05 was defined as statistically significant for all results. Result: Baseline PT at a cut-off value ≥ 16.25 seconds differentiated severe COVID-19 patients from mild and moderate patients (AUC: 0.89, 95% CI: 0.83–0.95). PT also differentiated mild COVID-19 patients from moderate and severe patients at a cut-off value ≤ 15.35 seconds (AUC: 0.90, 95% CI: 0.84–0.96). Moreover, alcohol drinkers were 3.52 times more likely chance of having severe disease than non-drinkers (95% CI: 1.41–8.81). A one-year increment in age also increased the odds of disease severity by 6% (95% CI: 3–9%). An increment of ≥ 0.65 seconds from the baseline PT predicted poor prognosis (AUC: 0.93, 0.87–0.99). Conclusions and recommendations: Prolonged baseline PT was observed in severe COVID-19 patients. Prolonged baseline PT was also predicted to worsen prognosis. An increase from the baseline PT was associated with worsen prognosis. Therefore, PT can be used as a risk stratification and prognostic marker in COVID-19 patients.

opencc-zeroDec 2016View details →

Data from: Prognostic value of cerebral tissue oxygen saturation during neonatal extracorporeal membrane oxygenation

Objectives: Extracorporeal membrane oxygenation support is indicated in severe and refractory respiratory or circulatory failures. Neurological complications are typically represented by acute ischemic or hemorrhagic lesions, which induce higher morbidity and mortality. The primary goal of this study was to assess the prognostic value of cerebral tissue oxygen saturation (StcO2) on mortality in neonates and young infants treated with ECMO. A secondary objective was to evaluate the association between StcO2 and the occurrence of cerebral lesions. Study Design: This was a prospective study in infants < 3 months of age admitted to a pediatric intensive care unit and requiring ECMO support. Measurements: The assessment of cerebral perfusion was made by continuous StcO2 monitoring using near-infrared spectroscopy (NIRS) sensors placed on the two temporo-parietal regions. Neurological lesions were identified by MRI or transfontanellar echography. Results: Thirty-four infants <3 months of age were included in the study over a period of 18 months. The ECMO duration was 10±7 days. The survival rate was 50% (17/34 patients), and the proportion of brain injuries was 20% (7/34 patients). The mean StcO2 during ECMO in the non-survivors was reduced in both hemispheres (p = 0.0008 right, p = 0.03 left) compared to the survivors. StcO2 was also reduced in deceased or brain-injured patients compared to the survivors without brain injury (p = 0.002). Conclusion: StcO2 appears to be a strong prognostic factor of survival and of the presence of cerebral lesions in young infants during ECMO.

Prognostic Value of Peak Lactate During Cardiopulmonary Bypass in Adult Cardiac Surgeries

ClinicalTrials.gov study NCT03934892. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.

Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS

ClinicalTrials.gov study NCT04573686. IPD Sharing: Not stated. Countries: 0. Publications: 6.

Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma

ClinicalTrials.gov study NCT01369784. IPD Sharing: Not stated. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →

Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study

ClinicalTrials.gov study NCT02814734. IPD Sharing: NO. Countries: 0. Publications: 14.

Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

ClinicalTrials.gov study NCT03046576. IPD Sharing: Not stated. Countries: 0. Publications: 6.